Clinical Trial

A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
QLC5508 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of QLC5508 in combination with other anti-cancer agents in patients with advanced solid tumor patients.
Trial Details
NCT Number NCT07256782
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Advanced Solid Tumor
Enrollment 444 participants
Start Date 2025-10-24
Primary Completion 2026-10 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2025-12-01